Biogen Reports Phase 3 subgroup analysis Data for Idelalisib in Systemic mastocytosis

Biogen today announced Phase 3 subgroup analysis results for Idelalisib in patients with Systemic mastocytosis. The study demonstrated that Idelalisib improves quality of life measures compared to standard of care or placebo. These results provide important insights into the treatment of Systemic mastocytosis and support the continued development of Idelalisib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Idelalisib was consistent with previous observations, with no new safety signals identified.